Markets:

Overview

News

Currencies

International

Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

6.660 +0.020 (+0.30%)

Delayed Quote Updated: 11:19 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

September 28, 2026

Via Chartmill

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

September 25, 2026

Via Chartmill

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

One of J&J's investments stands head-and-shoulders above the rest.

Via The Motley Fool

Adicet Bio: Q4 Earnings Insights ↗

March 19, 2024

Via Benzinga

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy ↗

August 11, 2026

Adicet Bio (NASDAQ:ACET) expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus...

Via MarketBeat

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 25, 2026

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH)...

Via Benzinga

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference ↗

June 04, 2026

Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen...

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 ↗

October 07, 2025

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $80 million to fund Phase 2.

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

October 07, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 19, 2025

Via Benzinga

Adicet Bio (ACET) Q2 Loss Widens 3% ↗

August 07, 2025

Via The Motley Fool

Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗

July 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 09, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

May 08, 2025

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 17, 2025

Via Benzinga

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe ↗

February 12, 2025

Via Stocktwits

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗

September 11, 2024

Via Benzinga

ACET Stock Earnings: Adicet Bio Beats EPS for Q2 2024 ↗

August 13, 2024

ACET stock results show that Adicet Bio beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 ↗

June 10, 2024

These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news

Via InvestorPlace

ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 ↗

May 14, 2024

ACET stock results show that Adicet Bio beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness ↗

March 28, 2024

Although speculation can be bad for your blood pressure, these compelling penny stocks have some strong endorsements.

Via InvestorPlace

ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023 ↗

March 19, 2024

ACET stock results show that Adicet Bio met analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

3 High-Risk Stocks That Could Pay Off in the Millions ↗

March 05, 2024

With the S&P 500 at record highs, betting on these high-risk stocks that could pay off is a tantalizing prospect at this time.

Via InvestorPlace

Topics Stocks

7 Top-Tier Penny Stocks for a Smart Bet ↗

February 27, 2024

Unlock value in penny stocks amid bullish S&P 500 trends and shifting monetary policies, focusing on businesses with solid drivers

Via InvestorPlace

Topics Stocks

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory ↗

February 25, 2024

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 22, 2024

Via Benzinga

IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data ↗

January 22, 2024

IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these...

Via Benzinga

Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 09, 2024

Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.